Pasireotide (Signifor)

pasireotide · Novartis

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Pasireotide (Signifor), covering 2026-03-04 to 2026-03-04. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Pasireotide in People With Prolactinoma [Phase 2]